CBUD Stock Overview
An exchange traded fund launched by BlackRock Asset Management Ireland Limited.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
iShares II Public Limited Company - iShares MSCI Europe SRI UCITS ETF Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €5.36 |
| 52 Week High | €5.65 |
| 52 Week Low | €4.43 |
| Beta | 0 |
| 11 Month Change | -1.31% |
| 3 Month Change | -1.31% |
| 1 Year Change | 16.25% |
| 33 Year Change | 4.89% |
| 5 Year Change | n/a |
| Change since IPO | 5.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| CBUD | DE Capital Markets | DE Market | |
|---|---|---|---|
| 7D | -0.5% | 1.4% | 0.2% |
| 1Y | 16.3% | 29.6% | 7.6% |
Return vs Industry: CBUD underperformed the German Capital Markets industry which returned 29.6% over the past year.
Return vs Market: CBUD exceeded the German Market which returned 7.6% over the past year.
Price Volatility
| CBUD volatility | |
|---|---|
| CBUD Average Weekly Movement | 2.0% |
| Capital Markets Industry Average Movement | 4.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CBUD has not had significant price volatility in the past 3 months.
Volatility Over Time: CBUD's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | n/a | n/a | www.ishares.com/uk/individual/en/products/251767/IESE |
iShares II Public Limited Company - iShares MSCI Europe SRI UCITS ETF is an exchange traded fund launched by BlackRock Asset Management Ireland Limited. The fund is managed by BlackRock Advisors (UK) Limited. It invests in the public equity markets of developed countries in Europe.
iShares II Public Limited Company - iShares MSCI Europe SRI UCITS ETF Fundamentals Summary
| CBUD fundamental statistics | |
|---|---|
| Market cap | €650.31m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs CBUD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CBUD income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CBUD perform over the long term?
See historical performance and comparison